HC Wainwright & Co. Reiterates Buy on VYNE Therapeutics, Maintains $5.75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on VYNE Therapeutics (NASDAQ:VYNE) with a maintained price target of $5.75.

May 06, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on VYNE Therapeutics with a price target of $5.75.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co., along with a specific price target, typically signals confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100